Q32 Bio Inc.
QTTB
$5.94
$0.132.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -68.00% | -43.88% | -7.42% | 97.58% | 35.14% |
| Gross Profit | 233.85% | 255.16% | 43.25% | -10.80% | 3.49% |
| SG&A Expenses | -5.44% | -1.56% | 1.97% | 21.02% | 44.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.08% | -44.28% | -30.64% | 2.19% | 37.64% |
| Operating Income | 133.72% | 125.57% | 43.78% | 17.52% | -13.93% |
| Income Before Tax | 155.62% | 162.50% | 30.29% | 7.84% | -31.20% |
| Income Tax Expenses | -- | -- | -91.70% | -93.40% | -93.40% |
| Earnings from Continuing Operations | 155.60% | 162.47% | 30.54% | 8.31% | -30.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 155.60% | 162.47% | 30.54% | 8.31% | -30.34% |
| EBIT | 133.72% | 125.57% | 43.78% | 17.52% | -13.93% |
| EBITDA | 134.55% | 126.36% | 43.97% | 17.59% | -14.08% |
| EPS Basic | 154.07% | 176.79% | 95.59% | 96.33% | 96.27% |
| Normalized Basic EPS | 128.19% | 132.46% | 92.17% | 94.39% | 94.58% |
| EPS Diluted | 153.85% | 122.18% | 95.97% | 96.54% | 96.46% |
| Normalized Diluted EPS | 128.05% | 128.31% | 92.25% | 94.42% | 94.60% |
| Average Basic Shares Outstanding | 5.53% | 32.20% | 92.26% | 256.16% | 2,268.95% |
| Average Diluted Shares Outstanding | 5.59% | 27.68% | 82.63% | 224.37% | 1,331.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |